Sign inJoin waitlistJoin the waitlist

Paul Goepfert

Physician · UAB Heersink School of Medicine

Credentials: · · ·

History

UAB Heersink School of Medicine · University of Alabama Hospital
Present

Infectious Disease
1994–1996
Internal Medicine
1991–1994
Baylor College of Medicine
1987–1991

Research

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
New England Journal of Medicine · 2021 · 1,938 citations
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
Proceedings of the National Academy of Sciences of the United States of America · 2008 · 1,563 citations
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
Blood · 2006 · 1,541 citations

Lindsey Baden
43 papers
Lawrence Corey
34 papers
Juliana McElrath
33 papers
Nathan Erdmann
24 papers · 2 as a fellow
MM
Mark Mulligan
23 papers
Kathleen Neuzil
22 papers
Jim Kublin
20 papers
Ann Falsey
18 papers
Michael Keefer
18 papers
NR
Nadine Rouphael
18 papers
Sharon Frey
18 papers
Sonya Heath
18 papers · 1 as a fellow

Grants

Onco-Immunologic Factors Contributing to OPSCC Among People Living with HIV
National Institute of Dental and Craniofacial Research · R01
PI · $2.1M · University of Alabama at Birmingham
2024–2029
UAB Center for AIDS Research (CFAR)
National Institute of Allergy and Infectious Diseases · P30
Project lead · $23M · University of Alabama at Birmingham
1997–2029
A-Z Clinical Trials Unit
National Institute of Allergy and Infectious Diseases · UM1
Contact PI · $9M · University of Alabama at Birmingham
2007–2027
Defining the Biological Relevance of HIV Specific HLA-E Restricted CD8 T Cell Responses
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $3M · University of Alabama at Birmingham
2021–2026

Clinical trials

Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
Study chair · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2018–2020
Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
Study chair · Completed · Phase 1, Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2017–2019
Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Study chair · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2017–2019
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
Study chair · Completed · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2009–2014